Sci Pharmtech Stock Current Valuation
| 4119 Stock | TWD 85.70 0.50 0.59% |
Valuation analysis of SCI Pharmtech helps investors to measure SCI Pharmtech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that SCI Pharmtech's price fluctuation is very steady at this time. Calculation of the real value of SCI Pharmtech is based on 3 months time horizon. Increasing SCI Pharmtech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the SCI stock is determined by what a typical buyer is willing to pay for full or partial control of SCI Pharmtech. Since SCI Pharmtech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of SCI Stock. However, SCI Pharmtech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 85.7 | Real 78.61 | Hype 85.7 | Naive 82.59 |
The intrinsic value of SCI Pharmtech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SCI Pharmtech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SCI Pharmtech helps investors to forecast how SCI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SCI Pharmtech more accurately as focusing exclusively on SCI Pharmtech's fundamentals will not take into account other important factors: SCI Pharmtech Company Current Valuation Analysis
SCI Pharmtech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current SCI Pharmtech Current Valuation | 9.19 B |
Most of SCI Pharmtech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SCI Pharmtech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, SCI Pharmtech has a Current Valuation of 9.19 B. This is 36.02% lower than that of the Pharmaceuticals sector and 23.61% higher than that of the Health Care industry. The current valuation for all Taiwan stocks is 44.72% higher than that of the company.
SCI Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SCI Pharmtech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SCI Pharmtech could also be used in its relative valuation, which is a method of valuing SCI Pharmtech by comparing valuation metrics of similar companies.SCI Pharmtech is currently under evaluation in current valuation category among its peers.
SCI Fundamentals
| Return On Equity | 0.0609 | |||
| Return On Asset | 0.0077 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 9.19 B | |||
| Shares Outstanding | 95.38 M | |||
| Shares Owned By Insiders | 48.80 % | |||
| Shares Owned By Institutions | 0.77 % | |||
| Price To Earning | 14.98 X | |||
| Price To Book | 2.62 X | |||
| Price To Sales | 11.33 X | |||
| Revenue | 864.22 M | |||
| Gross Profit | 208.09 M | |||
| EBITDA | 129.25 M | |||
| Net Income | 55.7 M | |||
| Cash And Equivalents | 1.01 B | |||
| Cash Per Share | 12.73 X | |||
| Total Debt | 3.65 M | |||
| Debt To Equity | 0.10 % | |||
| Current Ratio | 3.24 X | |||
| Book Value Per Share | 37.30 X | |||
| Cash Flow From Operations | 280.28 M | |||
| Earnings Per Share | 2.13 X | |||
| Target Price | 86.0 | |||
| Number Of Employees | 14 | |||
| Beta | -0.0933 | |||
| Market Capitalization | 9.59 B | |||
| Total Asset | 4.19 B | |||
| Retained Earnings | 809 M | |||
| Working Capital | 1.02 B | |||
| Current Asset | 1.8 B | |||
| Current Liabilities | 782 M | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 4.21 % | |||
| Net Asset | 4.19 B |
About SCI Pharmtech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SCI Pharmtech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SCI Pharmtech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SCI Pharmtech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for SCI Stock Analysis
When running SCI Pharmtech's price analysis, check to measure SCI Pharmtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SCI Pharmtech is operating at the current time. Most of SCI Pharmtech's value examination focuses on studying past and present price action to predict the probability of SCI Pharmtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SCI Pharmtech's price. Additionally, you may evaluate how the addition of SCI Pharmtech to your portfolios can decrease your overall portfolio volatility.